0001415889-24-022992.txt : 20240905 0001415889-24-022992.hdr.sgml : 20240905 20240905213005 ACCESSION NUMBER: 0001415889-24-022992 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240904 FILED AS OF DATE: 20240905 DATE AS OF CHANGE: 20240905 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cline Christopher R. CENTRAL INDEX KEY: 0001943192 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36257 FILM NUMBER: 241282808 MAIL ADDRESS: STREET 1: C/O TRAVERE THERAPEUTICS, INC. STREET 2: 3611 VALLEY CENTRE DRIVE, STE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Travere Therapeutics, Inc. CENTRAL INDEX KEY: 0001438533 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 262383102 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3611 VALLEY CENTRE DR STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 888-969-7879 MAIL ADDRESS: STREET 1: 3611 VALLEY CENTRE DR STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: Retrophin, Inc. DATE OF NAME CHANGE: 20130220 FORMER COMPANY: FORMER CONFORMED NAME: Desert Gateway, Inc. DATE OF NAME CHANGE: 20080625 4 1 form4-09052024_090901.xml X0508 4 2024-09-04 0001438533 Travere Therapeutics, Inc. TVTX 0001943192 Cline Christopher R. C/O TRAVERE THERAPEUTICS, INC. 3611 VALLEY CENTRE DRIVE, STE 300 SAN DIEGO CA 92130 false true false false CHIEF FINANCIAL OFFICER 0 Common Stock 2024-09-04 4 S 0 514 9.5093 D 70335 D Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. /s/ Elizabeth E. Reed, Attorney-in-Fact 2024-09-05